NASDAQ - Turning Point Therapeutics, Inc.

График котировок Turning Point Therapeutics, Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/BV 6.97
EV/EBITDA -47.49
EBITDA -0.1
Цена ао 115.76
P/S 223.06

Оценка

Недооценка

Название Значение Оценка
P/S 223.06 1
P/BV 6.97 1
P/E 0
EV/EBITDA -47.49 10

Эффективность

Название Значение Оценка
ROA, % -11.24 1
ROE, % -23.33 1

Дивиденды

Название Значение Оценка
Div yield, % 0
DSI 0 0

Долг

Название Значение Оценка
Долг/EBITDA 0

Импульс роста

Название Значение Оценка
Рост прибыли, % 0 0
Рост цены акции, % 0 0
Рост дивидендов, % 0 0

Основные владельцы

Institutions Объем Доля, %
Cormorant Asset Management, LLC 2442297 5.07
Peroni Portfolio Advisors, Inc 200 0
Burrage Capital Management LLC 78118 0.16
Wells Fargo Funds Management LLC 856784 1.78
Nicholas Investment Partners 10670 0.02
Fidelity SelectCo, LLC 4055125 8.42
Fidelity Management & Research Company LLC 6331381 13.14
PGIM Investments LLC 914771 1.9
Hartford Funds Management Company, LLC 668910 1.39
Federated MDTA LLC 222385 0.46
Orbimed Advisors, LLC 2745327 5.7
BNP Paribas Asset Management Luxembourg 241502 0.5
Munder Lee Investments Ltd 8117 0.02
Driehaus Capital Management (USVI) LLC 34985 0.07
Parkman Healthcare Partners LLC 110335 0.23
Osterweis Capital Management LLC 72545 0.15
AMG Funds LLC 29852 0.06
Sectoral Asset Management Inc 20950 0.04
New York Life Investment Management LLC 117209 0.24
MML Investment Advisers, LLC 98468 0.2
MPM Oncology Impact Management LP 308686 0.64
Fidelity Management & Research Company LLC 3492634 7.25
Prudential Retirement Services 81178 0.17
American Century Investment Management, Inc 801697 1.66
Nationwide Fund Advisors 139042 0.29

Содержится в ETF

ETF Доля, % Доходность за год, %
Defiance Nasdaq Junior Biotechnology ETF 1.36

Похожие компании

Описание Turning Point Therapeutics, Inc.

Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I\u002FII trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET\u002FSRC inhibitor; TPX-0022, a MET\u002FCSF1R\u002FSRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.